Frankfurt
25.04.25
15:29 Uhr
1,676 Euro
-0,024
-1,41 %
-1,41 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Advicenne: Fiscal Year 2024 Marked by the Satisfactory Commercial Performance of Sibnayal in Europe and Development in the United States | 387 | Business Wire | Total product sales of Advicenne up 9.4% to €4.9m
Operating cash consumption below €1M by 2025 and significant improvement in cash flow
Cash position of €3.2 million on December... ► Artikel lesen | |
| ADVICENNE Aktie jetzt für 0€ handeln | |||||
| 29.01. | Advicenne Reaches a Significant Milestone With the US FDA in the Development of ADV7103 in Cystinuria | 330 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746) a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 23.01. | Advicenne Announces 2024 Gross Sales1 | 350 | Business Wire | 2024 Gross sales reported at €4.8 million, up 9.2%. Gross sales of Sibnayal® (potassium citrate potassium bicarbonate) in France recorded an impressive 40% growth. Royalties for 2024... ► Artikel lesen | |
| 19.12.24 | Advicenne Finalizes Agreement with Primex Pharmaceuticals AG | 436 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 28.11.24 | Advicenne Announces its 2025 Financial Calendar | 134 | Business Wire | Regulatory News:
Advicenne(Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 01.10.24 | Advicenne achieves major milestones in the US thanks to several positive FDA opinions on ADV7103 | 396 | Business Wire | FDA agrees to submission of a marketing authorization application for ADV7103 in dRTA without further clinical studies. The positive orphan drug designation decision for ADV7103 in cystinuria... ► Artikel lesen | |
| 18.09.24 | Advicenne Reports Its First Half Financial Results as of June 30, 2024, and Updates on Its Activities | 414 | Business Wire | Sibnayal® gross sales up 28% to €1.25 million including royalties paid by commercial partners (16% excluding royalties) Continued progress towards current operating breakeven Cash... ► Artikel lesen | |
| 18.07.24 | Advicenne Announces an 8.8% Increase in Gross Sales for H1 2024 and Provides an Update on Its Activities | 360 | Business Wire | Regulatory News:
Advicenne (Euronext Growth Paris ALDVI FR0013296746), a specialty pharmaceutical company dedicated to the development and commercialization of innovative treatments for those suffering... ► Artikel lesen | |
| 15.05.24 | Advicenne Announces the Approval of All Resolutions Supported by the Board of Directors at Its Combined General Meeting | 294 | Business Wire | Regulatory News:
The Combined General Meeting of shareholders of Advicenne (Euronext Growth Paris ALDVI FR0013296746) (Paris:ALDVI), a specialty pharmaceutical company dedicated to the development... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,195 | -0,02 % | Ihre wichtigsten Termine: Alle Blicke auf: Intel, Pepsico, Pfizer, Boeing, Nestle, Asos, Johnson & Johnson | © Foto: Intel CorporationGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| ABBVIE | 164,60 | +0,37 % | ABBVIE mit Prognosesenkung | Der Biopharmakonzern rechnet mit Zusatzkosten in Höhe von 248 Mio. $ im Zusammenhang mit Übernahmen, darunter Meilensteinzahlungen sowie F&E-Aufwendungen. Hintergrund ist der strategische Fokus auf... ► Artikel lesen | |
| HAEMATO | 13,600 | -2,86 % | HAEMATO Aktie: Grund zur Freude bei Investoren | Das Pharma-Unternehmen plant eine strategische Fokussierung auf den wachstumsstarken Bereich der ästhetischen Medizin und prüft derzeit ein konkretes Kaufangebot. HAEMATO erwägt derzeit den Verkauf... ► Artikel lesen | |
| HALEON | 4,473 | +0,31 % | Dividendenbekanntmachungen (24.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADF GROUP INC CA00089N1033 0,02 CAD 0,0127 EUR ALPHA GROUP INTERNATIONAL PLC GB00BF1TM596 0,14 GBP 0,1638 EUR AQ GROUP AB SE0022062196 1... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 92,00 | -3,16 % | Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries... ► Artikel lesen | |
| ACHIEVE LIFE SCIENCES | 2,080 | -0,95 % | Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine | ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission... ► Artikel lesen | |
| ROYALTY PHARMA | 27,970 | -1,34 % | Royalty Pharma declares $0.22 dividend | ||
| TG THERAPEUTICS | 36,000 | -0,94 % | MaxCyte, Inc: MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs | ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery... ► Artikel lesen | |
| EISAI | 24,810 | -0,76 % | Eisai Aktie: Zwischen Bewertung und Skepsis | Eisais Aktie zeigt schwache Performance bei niedrigen Bewertungen. Analysten uneins vor entscheidendem Quartalsbericht im Mai. Die Eisai-Aktie zeigt sich derzeit in einer volatilen Phase. Am 17. April... ► Artikel lesen | |
| DR REDDYS | 12,200 | +1,67 % | DR REDDYS LABORATORIES LTD - 6-K, Report of foreign issuer | ||
| VERONA PHARMA PLC ADR | 57,00 | -1,04 % | Verona Pharma plc - 8-K, Current Report | ||
| BETTERLIFE PHARMA | 0,057 | 0,00 % | BETTERLIFE HLDG (06909): DISCLOSEABLE TRANSACTIONS IN RELATION TO THE ASSETS TRANSFER AGREEMENT AND THE YANBAO LEASE AGREEMENT | ||
| ENTOURAGE HEALTH | 0,001 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 08.04.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 08.04.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 08.04.2025ISIN NameCA2938611001 ENTOURAGE... ► Artikel lesen | |
| IGC PHARMA | 0,266 | +1,53 % | IGC Pharma, Inc.: IGC Pharma Welcomes Strategic Investment from Advisors | POTOMAC, MARYLAND / ACCESS Newswire / April 24, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced that the Company's recently appointed advisors entered into a Share... ► Artikel lesen | |
| KYOWA KIRIN | 13,700 | +0,74 % | Kura Oncology, Inc.: Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA | SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, "Kura"), and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin"), today announced Kura submitted a New Drug... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADVICENNE finden Sie auf Wallstreet Online.
